Method for producing transgenic cell
A method for producing a transgenic cell, may include contacting, in vitro, (i) a virus comprising: a chimeric protein of an antibody-binding protein and a vesicular stomatitis virus G (VSV-G) protein; and a foreign gene, with (ii) a target cell and an antibody specific to the target cell, and/or a target cell comprising a membrane antibody, to infect the target cell with the virus.
1. A method for producing a transgenic cell, comprising:
(a) contacting, in vitro, an antigen of a target cell with an antibody specific to the target cell;
and then contacting, in vitro:
(i) a virus comprising: a chimeric protein of an antibody-binding protein and a vesicular stomatitis virus G (VSV-G) protein; and a foreign gene, with
(ii) the antibody specific to the target cell that is in contact with the antigen of the target cell, and/or,
(b) contacting, in vitro:
(i) the virus comprising: the chimeric protein of the antibody-binding protein and the vesicular stomatitis virus G (VSV-G) protein; and the foreign gene, with
(ii) a membrane antibody of a B cell, to infect the target cell with the virus.
2. The method for producing a transgenic cell according to claim 1 , wherein the antibody-binding protein comprises either one or both of an IgG-binding domain of protein A and an IgG-binding domain of protein L.
3. The method for producing a transgenic cell according to claim 2 , wherein the antibody-binding protein comprises 3 or more IgG-binding domains of protein A.
4. The method for producing a transgenic cell according to claim 2 , wherein the antibody-binding protein comprises 3 or more IgG-binding domains of protein L.
5. The method for producing a transgenic cell according to claim 1 , wherein, in the chimeric protein, the antibody-binding protein is present at the N-terminal side of the vesicular stomatitis virus G (VSV-G) protein.
6. The method for producing a transgenic cell according to claim 1 , wherein the virus is a retrovirus.
7. The method for producing a transgenic cell according to claim 6 , wherein the retrovirus is a lentivirus.
8. The method for producing a transgenic cell according to claim 1 , wherein the target cell is at least one of a human primary cell, a human induced pluripotent stem cell (iPS cell), a human embryonic stem cell (ES cell), a human mesenchymal stem cell, and cells differentiated and induced from said cells.
9. The method for producing a transgenic cell according to claim 1 , wherein the target cell is a peripheral blood mononuclear cell.
10. The method for producing a transgenic cell according to claim 1 , wherein the target cell is human B cell, human T cell or a human mesenchymal stem cell.
11. The method for producing a transgenic cell according to claim 1 , wherein the target cell is human T cell; and the antibody specific to the target cell is at least one selected from an anti-human CD3 antibody, an anti-human CD8a antibody and an anti-human CD11a antibody.
12. The method for producing a transgenic cell according to claim 1 , wherein the target cell is human B cell; and the virus is contacted with the target cell in vitro in the presence of at least one stimulus selected from a stimulus via IL-4, ODN 2006 and CD40 receptors and a stimulus via a BAFF receptor.
13. The method for producing a transgenic cell according to claim 1 , wherein the target cell is a human mesenchymal stem cell; and the antibody specific to the target cell is an anti-human CD90 antibody.
14. The method for producing a transgenic cell according to claim 1 , wherein the virus comprising a chimeric protein of an antibody-binding protein and a vesicular stomatitis virus G (VSV-G) protein comprises vesicular stomatitis virus G (VSV-G) protein in addition to the chimeric protein.
15. The method for producing a transgenic cell according to claim 14 , wherein a molar ratio of the chimeric protein and the vesicular stomatitis virus G (VSV-G) protein in the virus falls within a range of 1:1 to 1:512.
16. The method for producing a transgenic cell according to claim 1 , wherein the virus comprising a chimeric protein of an antibody-binding protein and a vesicular stomatitis virus G (VSV-G) protein is produced by using a plasmid vector which contains a nucleotide sequence encoding the chimeric protein of an antibody-binding protein and a vesicular stomatitis virus G (VSV-G) protein, in combination with a plasmid vector which does not comprise a nucleotide sequence encoding the antibody-binding protein and comprises a nucleotide sequence encoding the vesicular stomatitis virus G (VSV-G) protein.
17. The method for producing a transgenic cell according to claim 16 , wherein a mass ratio of the plasmid vector which does not comprise a nucleotide sequence encoding the antibody-binding protein and comprises a nucleotide sequence encoding the vesicular stomatitis virus G (VSV-G) protein, and a plasmid vector which comprises a nucleotide sequence encoding the chimeric protein of an antibody-binding protein and a vesicular stomatitis virus G (VSV-G) protein falls within a range of 64:1 to 64:256.